Hong-Ming Hu: Scaling TCR-T for solid tumors through ImmuXell's partnership with IRO®
Jul 2, 2026 - 00:45:45
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Carl Schoellhammer: viability is the crucial third pillar in CGT
In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene the...
Related Episodes
Continue listening to more episodes from Ori Spotlight.
Ken Harris: Why AI and automation are CGT’s next inflection point
Jan 27, 2026 - 01:03:25
Joe DePinto: Why advanced therapies need a new delivery model
Jan 13, 2026 - 01:04:41
Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy
Dec 16, 2025 - 00:55:35
Warner Biddle: Building a commercial model for CAR-T in autoimmune care
Sep 2, 2025 - 00:40:41
Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success
Aug 12, 2025 - 01:00:07
Henrik Andersen: How smart planning helps CGT scale further, faster
Jul 15, 2025 - 00:54:20